Free Trial

Vera Therapeutics (VERA) Competitors

Vera Therapeutics logo
$30.33 +0.13 (+0.43%)
Closing price 10/21/2025 04:00 PM Eastern
Extended Trading
$30.34 +0.01 (+0.03%)
As of 10/21/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VERA vs. ABVX, RNA, CYTK, MRUS, RYTM, CRSP, GRFS, NUVL, AXSM, and LEGN

Should you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Merus (MRUS), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Grifols (GRFS), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

Vera Therapeutics vs. Its Competitors

Abivax (NASDAQ:ABVX) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Abivax's return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AbivaxN/A N/A N/A
Vera Therapeutics N/A -46.70%-39.46%

47.9% of Abivax shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Abivax has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

In the previous week, Vera Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 8 mentions for Vera Therapeutics and 4 mentions for Abivax. Vera Therapeutics' average media sentiment score of 0.69 beat Abivax's score of 0.47 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abivax
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vera Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Abivax presently has a consensus price target of $114.25, indicating a potential upside of 24.63%. Vera Therapeutics has a consensus price target of $61.50, indicating a potential upside of 102.77%. Given Vera Therapeutics' higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abivax
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91
Vera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbivaxN/AN/A-$190.71MN/AN/A
Vera TherapeuticsN/AN/A-$152.15M-$3.58-8.47

Summary

Vera Therapeutics beats Abivax on 7 of the 12 factors compared between the two stocks.

Get Vera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERA vs. The Competition

MetricVera TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.93B$3.47B$6.21B$10.68B
Dividend YieldN/A2.27%5.72%4.88%
P/E Ratio-8.4723.0629.1427.23
Price / SalesN/A497.37587.91132.66
Price / CashN/A47.5937.5161.65
Price / Book3.3410.6612.526.59
Net Income-$152.15M-$52.56M$3.32B$276.14M
7 Day Performance-2.16%2.64%0.77%-0.72%
1 Month Performance16.16%13.86%7.29%2.47%
1 Year Performance-25.50%14.85%64.58%33.90%

Vera Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VERA
Vera Therapeutics
2.8909 of 5 stars
$30.33
+0.4%
$61.50
+102.8%
-25.8%$1.93BN/A-8.4740
ABVX
Abivax
3.5041 of 5 stars
$95.63
+2.0%
$114.25
+19.5%
+773.0%$7.30BN/A0.0061Short Interest ↓
RNA
Avidity Biosciences
2.6335 of 5 stars
$48.96
-1.6%
$68.32
+39.5%
+5.0%$7.26B$10.90M-13.75190
CYTK
Cytokinetics
3.8703 of 5 stars
$59.59
-0.7%
$76.64
+28.6%
+7.4%$7.18B$18.47M-11.68250Trending News
Analyst Forecast
Insider Trade
MRUS
Merus
1.4852 of 5 stars
$94.85
+0.5%
$93.12
-1.8%
+83.3%$7.14B$36.13M-17.2537Short Interest ↓
RYTM
Rhythm Pharmaceuticals
3.0379 of 5 stars
$100.77
0.0%
$106.64
+5.8%
+113.5%$6.70B$130.13M-33.48140Insider Trade
CRSP
CRISPR Therapeutics
1.957 of 5 stars
$68.29
-6.5%
$71.71
+5.0%
+49.1%$6.65B$37.31M-12.58460Insider Trade
Gap Up
GRFS
Grifols
4.0519 of 5 stars
$9.45
+1.4%
$10.30
+9.0%
+9.0%$6.41B$7.81B8.0823,822Positive News
NUVL
Nuvalent
2.6314 of 5 stars
$89.75
+1.9%
$118.89
+32.5%
-3.9%$6.35BN/A-18.3240Analyst Revision
AXSM
Axsome Therapeutics
4.7844 of 5 stars
$121.15
-0.5%
$177.93
+46.9%
+43.6%$6.07B$385.69M-23.90380Positive News
Analyst Forecast
LEGN
Legend Biotech
2.9421 of 5 stars
$32.85
+3.6%
$69.25
+110.8%
-24.4%$5.85B$627.24M-37.332,609High Trading Volume

Related Companies and Tools


This page (NASDAQ:VERA) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners